UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
Dr. Ashwani Kumar Sharma explains why a persistent cough lasting over three weeks should not be ignored, highlighting key lung cancer symptoms, diagnosis, and treatment options.
Chronic kidney disease is increasing in India and often goes unnoticed until late stages. Experts highlight the warning signs and preventive steps that can help protect kidney health ...
Tuberculosis has come under the spotlight in Malaysia recently, with reports of 10 active TB clusters in the country. In the ...
Excessive sweating beyond heat or exercise could signal hyperhidrosis. Know its causes, warning signs, treatment options, and when to consult a doctor.
Leading pharmacists have warned that widely used over-the-counter anti-inflammatory drugs like Ibuprofen may increase the risk of deadly kidney disease. Experts at Kidney Care UK and the National ...
New presentations for tildrakizumab-asmn explore real-world use in U.S. patients using Medicare New data specific to patients with skin of color expands ...
The Ministry of Health recorded 503 new TB cases in the fifth Epidemiological Week of 2026, bringing the cumulative total so far this year to 2,571 cases, according to the New Straits Times .
A substantial portion of the cases I see in the clinic are prospective overseas workers who test positive on screening for infectious diseases during ...
Leading pharmacists have warned that widely used over-the-counter anti-inflammatory drugs like Ibuprofen may increase the risk of deadly kidney disease. Experts at Kidney Care UK and the National ...
Chronic cough has not traditionally been listed as a common adverse effect of GLP-1s. According to Jeff Stanley, MD, president of the Virta Medical Professional Corporation of Denver-based Virta ...
Primary endpoint showing superiority met: Bimekizumab achieved statistically significant superiority over risankizumab in reducing disease activity, as measured by the stringent ACR50 endpoint, at ...